Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JASPAC04: Neoadjuvant S-1 chemoradiotherapy vs gemcitabine + S-1 for resectable pancreatic cancer
jRCTs041180051Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in pancreatic adenocarcinoma (PDAC) comparing S-1 chemoradiotherapy arm with Gemcitabine + S-1 chemotherapy arm (2 arms). Primary endpoint: 2-year progression-free survival. Started Oct 2014; status: completed.
02
Drugs
tegafurgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCTs041180051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180051.